The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of ctDNA in patients with mCRPC with liver metastases.
 
Minqi Huang
No Relationships to Disclose
 
Georges Gebrael
No Relationships to Disclose
 
Nicolas Sayegh
No Relationships to Disclose
 
Crystal Casado
No Relationships to Disclose
 
Nicholas Habibian
No Relationships to Disclose
 
Opeoluwa Akerele
No Relationships to Disclose
 
Kanika Gupta
No Relationships to Disclose
 
Alexandra Lieberman
No Relationships to Disclose
 
Jennifer Schwartz
No Relationships to Disclose
 
Jodi Lyn Layton
No Relationships to Disclose
 
Patrick L Sweeney
No Relationships to Disclose
 
Brian E. Lewis
No Relationships to Disclose
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
A. Oliver Sartor
Stock and Other Ownership Interests - Abbvie; Cardinal Health; Clarity Pharmaceuticals; Convergent Therapeutics; Fusion Pharmaceuticals; Lilly; POINT Biopharma; PSMA Therapeutics; Ratiopharm; Telix Pharmaceuticals; United Health Group
Honoraria - Lantheus Medical Imaging
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; ARTbio; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Clarity Pharmaceuticals; Clovis Oncology; Constellation Pharmaceuticals; Dendreon; EMD Serono; Fusion Pharmaceuticals; Hengrui Therapeutics; Isotopen Technologien; Janssen; MacroGenics; Medscape; Merck; Morphimmune; Myovant Sciences; Myriad Genetics; Noria Therapeutics; Northstar; Novartis; Noxopharm; Pfizer; Point Biopharma; Progenics; Ratio; Sanofi; Telix Pharmaceuticals; TEmpus; TeneoBio; Tessa Therapeutics; Theragnostics
Research Funding - Advanced Accelerator Applications (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Endocyte (Inst); InVitae (Inst); Janssen; Lantheus Medical Imaging (Inst); Merck (Inst); Progenics; Sanofi (Inst); SOTIO
Patents, Royalties, Other Intellectual Property - Koochekpour, Sartor AO, inventors. Saposin C and receptors as targets for treatment of benign and malignant disorders. US patent awarded January 23, 2007 (patent no. 7,166,691).
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Lantheus Medical Imaging; Progenics; Sanofi
 
Elisa M. Ledet
No Relationships to Disclose